Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
4 In TRANSCEND-T2D-1, Lillys first Phase 3 trial in adults with type 2 diabetes (537 participants, 40 weeks), retatrutide produced 16.8% weight loss at the 12 mg dose
The data also carries a warning for states that might assume they are insulated by size or healthcare infrastructure
But we have to drop this judgment and shame
Wegovy for Weight Loss Wegovy received FDA approval in 2021
Tirzepatide, a single-molecule agonist of both GLP-1 and GIPR, demonstrated remarkable efficacy in the SURPASS and SURMOUNT clinical trial programs
Among 169,649 patients with MASLD, GLP-1 receptor agonist initiation was linked to significantly lower probability of incident cirrhosis [adjusted hazard ratio (aHR): 0.86, 95%CI: 0.80-0.93], hepatic decompensation (aHR: 0.77, 95%CI: 0.65-0.90), and hepatocellular carcinoma (HCC) (aHR: 0.79, 95%CI: 0.68-0.92) over a median follow-up of 3.5 years compared to non-users
US$ 26.64
US$ 21.49
US$ 25.95
US$ 21.43
US$ 20.58
US$ 23.75
US$ 20.95
US$ 23.46
